Evidence map›Paper›PMID 40329079›Full record

ArticleThe Journal of antibiotics2025

Evaluation of lung epithelial lining fluid concentrations of lascufloxacin against Streptococcus pneumoniae in a hollow-fiber infection model.

Haruka Nakagawa Kamura, Tetsuo Yamaguchi, Toshihiro Kasama, Yukitaka Hayashi, Masakaze Hamada, Kazuaki Matsumoto, Ryo Miyake, Yoshikazu Ishii

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Haruka Nakagawa KamuraMicrobial Genomics and Ecology, Center for the Planetary Health and Innovation Science (PHIS), The IDEC Institute, Hiroshima University, Hiroshima, Japan.
Tetsuo YamaguchiDepartment of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan.
Toshihiro KasamaDepartment of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.
Yukitaka HayashiDivision of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Masakaze HamadaDepartment of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan.
Kazuaki MatsumotoDivision of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Ryo MiyakeDepartment of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.
Yoshikazu IshiiMicrobial Genomics and Ecology, Center for the Planetary Health and Innovation Science (PHIS), The IDEC Institute, Hiroshima University, Hiroshima, Japan. ishiiyo@hiroshima-u.ac.jp.

Funding

Japan Agency for Medical Research and Development (AMED) 22fk0108604h1002
6 · The paper itself

Abstract

Lascufloxacin (LSFX) achieves concentrations in epithelial lining fluid (ELF) that are more than 15 times higher than those in the bloodstream, making it a promising candidate for respiratory and otorhinolaryngological infections. These concentrations were replicated using the Hollow-Fiber Infection Model and demonstrated bactericidal efficacy of LSFX against levofloxacin-sensitive and -resistant Streptococcus pneumoniae. The study confirms that LSFX's elevated concentration in ELF plays a significant role in its bactericidal activity.

Indexed as

Anti-Bacterial AgentsFluoroquinolonesLungPneumococcal InfectionsStreptococcus pneumoniaeAnimalsDisease Models, AnimalHumansLevofloxacinMicrobial Sensitivity TestsAnti-Bacterial AgentsFluoroquinolonesLevofloxacin

Identifiers

PMID40329079
PMCPMC12106058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.